Indication
Rectosigmoid Cancer
1 clinical trial
1 product
2 drugs
Clinical trial
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trialStatus: Completed, Estimated PCD: 2021-01-11
Drug
mFOLFOX6Drug
5-FUProduct
Aflibercept